Cargando…
FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy
BACKGROUND: The aim was to investigate the correlation between (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) metabolic response to chemoradiotherapy and clinical outcomes in squamous cell carcinoma (SCC) of the anus. METHODS: A total of 48 patients with biopsy-proven anal SCC under...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170972/ https://www.ncbi.nlm.nih.gov/pubmed/21792197 http://dx.doi.org/10.1038/bjc.2011.274 |
_version_ | 1782211700708081664 |
---|---|
author | Day, F L Link, E Ngan, S Leong, T Moodie, K Lynch, C Michael, M Winton, E de Hogg, A Hicks, R J Heriot, A |
author_facet | Day, F L Link, E Ngan, S Leong, T Moodie, K Lynch, C Michael, M Winton, E de Hogg, A Hicks, R J Heriot, A |
author_sort | Day, F L |
collection | PubMed |
description | BACKGROUND: The aim was to investigate the correlation between (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) metabolic response to chemoradiotherapy and clinical outcomes in squamous cell carcinoma (SCC) of the anus. METHODS: A total of 48 patients with biopsy-proven anal SCC underwent FDG-PET scans at baseline and post chemoradiotherapy (54 Gy, concurrent 5-FU/mitomycin). Kaplan–Meier analysis was used to determine survival outcomes according to FDG-PET metabolic response. RESULTS: In all, 79% patients (n=38) had a complete metabolic response (CMR) at all sites of disease, 15% (n=7) had a CMR in regional nodes but only partial response in the primary tumour (overall partial metabolic response (PMR)) and 6% (n=3) had progressive distant disease despite CMR locoregionally (overall no response (NR)). The 2-year progression-free survival (PFS) was 95% for patients with a CMR, 71% for PMR and 0% for NR (P<0.0001). The 5-year overall survival (OS) was 88% in CMR, 69% in PMR and 0% in NR (P<0.0001). Cox proportional hazards regression analyses for PFS and OS found significant associations for incomplete (PMR+NR) vs complete FDG-PET response to treatment only, (HR 4.1 (95% CI: 1.5–11.5, P=0.013) and 6.7 (95% CI: 2.1–21.6, P=0.002), respectively). CONCLUSION: FDG-PET metabolic response to chemoradiotherapy in anal cancer is significantly associated with PFS and OS, and in this cohort incomplete FDG-PET response was a stronger predictor than T or N stage. |
format | Online Article Text |
id | pubmed-3170972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-31709722012-08-09 FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy Day, F L Link, E Ngan, S Leong, T Moodie, K Lynch, C Michael, M Winton, E de Hogg, A Hicks, R J Heriot, A Br J Cancer Clinical Study BACKGROUND: The aim was to investigate the correlation between (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) metabolic response to chemoradiotherapy and clinical outcomes in squamous cell carcinoma (SCC) of the anus. METHODS: A total of 48 patients with biopsy-proven anal SCC underwent FDG-PET scans at baseline and post chemoradiotherapy (54 Gy, concurrent 5-FU/mitomycin). Kaplan–Meier analysis was used to determine survival outcomes according to FDG-PET metabolic response. RESULTS: In all, 79% patients (n=38) had a complete metabolic response (CMR) at all sites of disease, 15% (n=7) had a CMR in regional nodes but only partial response in the primary tumour (overall partial metabolic response (PMR)) and 6% (n=3) had progressive distant disease despite CMR locoregionally (overall no response (NR)). The 2-year progression-free survival (PFS) was 95% for patients with a CMR, 71% for PMR and 0% for NR (P<0.0001). The 5-year overall survival (OS) was 88% in CMR, 69% in PMR and 0% in NR (P<0.0001). Cox proportional hazards regression analyses for PFS and OS found significant associations for incomplete (PMR+NR) vs complete FDG-PET response to treatment only, (HR 4.1 (95% CI: 1.5–11.5, P=0.013) and 6.7 (95% CI: 2.1–21.6, P=0.002), respectively). CONCLUSION: FDG-PET metabolic response to chemoradiotherapy in anal cancer is significantly associated with PFS and OS, and in this cohort incomplete FDG-PET response was a stronger predictor than T or N stage. Nature Publishing Group 2011-08-09 2011-07-26 /pmc/articles/PMC3170972/ /pubmed/21792197 http://dx.doi.org/10.1038/bjc.2011.274 Text en Copyright © 2011 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Day, F L Link, E Ngan, S Leong, T Moodie, K Lynch, C Michael, M Winton, E de Hogg, A Hicks, R J Heriot, A FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy |
title | FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy |
title_full | FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy |
title_fullStr | FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy |
title_full_unstemmed | FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy |
title_short | FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy |
title_sort | fdg-pet metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170972/ https://www.ncbi.nlm.nih.gov/pubmed/21792197 http://dx.doi.org/10.1038/bjc.2011.274 |
work_keys_str_mv | AT dayfl fdgpetmetabolicresponsepredictsoutcomesinanalcancermanagedwithchemoradiotherapy AT linke fdgpetmetabolicresponsepredictsoutcomesinanalcancermanagedwithchemoradiotherapy AT ngans fdgpetmetabolicresponsepredictsoutcomesinanalcancermanagedwithchemoradiotherapy AT leongt fdgpetmetabolicresponsepredictsoutcomesinanalcancermanagedwithchemoradiotherapy AT moodiek fdgpetmetabolicresponsepredictsoutcomesinanalcancermanagedwithchemoradiotherapy AT lynchc fdgpetmetabolicresponsepredictsoutcomesinanalcancermanagedwithchemoradiotherapy AT michaelm fdgpetmetabolicresponsepredictsoutcomesinanalcancermanagedwithchemoradiotherapy AT wintonede fdgpetmetabolicresponsepredictsoutcomesinanalcancermanagedwithchemoradiotherapy AT hogga fdgpetmetabolicresponsepredictsoutcomesinanalcancermanagedwithchemoradiotherapy AT hicksrj fdgpetmetabolicresponsepredictsoutcomesinanalcancermanagedwithchemoradiotherapy AT heriota fdgpetmetabolicresponsepredictsoutcomesinanalcancermanagedwithchemoradiotherapy |